Close

GenMark Diagnostics Receives FDA Clearance for its ePlex Blood Culture Identification Gram Negative Panel

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Haleon Breaks Ground on new £130m Global Oral Health Innovation Centre

This week, Haleon, a global leader in consumer health...

Evonik Opens New Medical Device Center in Shanghai

The company’s largest center for medical device applications,...

GenMark Diagnostics has received FDA 510(k) market clearance from the U.S. FDA for its ePlex Blood Culture Identification Gram-Negative (BCID-GN) Panel.This is the third ePlex BCID Panel to receive FDA clearance during the past four months. GenMark’s complete family of ePlex BCID Panels, including the Gram-Negative (BCID-GN), Gram-Positive (BCID-GP) and Fungal Pathogen (BCID-FP) Panels, were developed on the Company’s ePlex sample-to-answer system for the diagnosis and disease management of bloodstream infections (BSI) that can lead to sepsis.

“The ePlex BCID Panels provide broad coverage of organisms and resistance markers that can lead to sepsis, including anaerobes and multidrug resistant organisms (MDRO), as well as common and emerging fungal pathogens. We are excited to bring to market the most comprehensive molecular test solution designed to improve the diagnosis and management of bloodstream infections, while delivering economic and quality benefits to our customers,” said Hany Massarany, President and Chief Executive Officer.

“We believe that the potential market opportunity for our BCID Panels could be as large as the available market for our Respiratory Pathogen (RP) Panel, which we estimate to be around $500 million globally. We expect BCID to be a key contributor to our 2019 performance, driving both ePlex placements and assay sales,” added Massarany.

Latest stories

Related stories

Haleon Breaks Ground on new £130m Global Oral Health Innovation Centre

This week, Haleon, a global leader in consumer health...

Evonik Opens New Medical Device Center in Shanghai

The company’s largest center for medical device applications,...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back